IL324206A - Inhibitors of jun n-terminal kinases (jnk1, jnk2, and/or jnk3) and mitogen-activated protein kinases (mapk8, mapk9, and/or mapk10) and methods of using same - Google Patents

Inhibitors of jun n-terminal kinases (jnk1, jnk2, and/or jnk3) and mitogen-activated protein kinases (mapk8, mapk9, and/or mapk10) and methods of using same

Info

Publication number
IL324206A
IL324206A IL324206A IL32420625A IL324206A IL 324206 A IL324206 A IL 324206A IL 324206 A IL324206 A IL 324206A IL 32420625 A IL32420625 A IL 32420625A IL 324206 A IL324206 A IL 324206A
Authority
IL
Israel
Prior art keywords
carboxamide
pyrrolo
pyridin
benzo
cdd
Prior art date
Application number
IL324206A
Other languages
English (en)
Hebrew (he)
Inventor
Chandra Madasu
Stephen Palmer
Martin Matzuk
Diana Monsivais
Kurt Bohren
Zhi Tan
Jian-Yuan Li
Feng Li
Damian Young
Kiran Sharma
Murugesan Palaniappan
Srinivas Chamakuri
Ramakrishna Kommagani
Original Assignee
Baylor College Medicine
Chandra Madasu
Stephen Palmer
Martin Matzuk
Diana Monsivais
Kurt Bohren
Zhi Tan
Li jian yuan
Feng Li
Damian Young
Kiran Sharma
Murugesan Palaniappan
Srinivas Chamakuri
Ramakrishna Kommagani
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College Medicine, Chandra Madasu, Stephen Palmer, Martin Matzuk, Diana Monsivais, Kurt Bohren, Zhi Tan, Li jian yuan, Feng Li, Damian Young, Kiran Sharma, Murugesan Palaniappan, Srinivas Chamakuri, Ramakrishna Kommagani filed Critical Baylor College Medicine
Publication of IL324206A publication Critical patent/IL324206A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/547—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL324206A 2023-04-24 2025-10-26 Inhibitors of jun n-terminal kinases (jnk1, jnk2, and/or jnk3) and mitogen-activated protein kinases (mapk8, mapk9, and/or mapk10) and methods of using same IL324206A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363461485P 2023-04-24 2023-04-24
PCT/US2024/025997 WO2024226609A2 (en) 2023-04-24 2024-04-24 Inhibitors of jun n-terminal kinases (jnk1, jnk2, and/or jnk3) and mitogen-activated protein kinases (mapk8, mapk9, and/or mapk10) and methods of using same

Publications (1)

Publication Number Publication Date
IL324206A true IL324206A (en) 2025-12-01

Family

ID=93257454

Family Applications (1)

Application Number Title Priority Date Filing Date
IL324206A IL324206A (en) 2023-04-24 2025-10-26 Inhibitors of jun n-terminal kinases (jnk1, jnk2, and/or jnk3) and mitogen-activated protein kinases (mapk8, mapk9, and/or mapk10) and methods of using same

Country Status (7)

Country Link
EP (1) EP4704828A2 (de)
KR (1) KR20260025078A (de)
CN (1) CN121368479A (de)
AU (1) AU2024262149A1 (de)
IL (1) IL324206A (de)
MX (1) MX2025012789A (de)
WO (1) WO2024226609A2 (de)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR046078A1 (es) * 2003-08-06 2005-11-23 Senomyx Inc Nuevos sabores, modificadores de sabores, sustancias gustativas, mejoradores de gusto, sustancias gustativas y/o mejoradoras del gusto umani o dulce y uso de los mismos.

Also Published As

Publication number Publication date
WO2024226609A3 (en) 2025-03-27
EP4704828A2 (de) 2026-03-11
KR20260025078A (ko) 2026-02-23
WO2024226609A2 (en) 2024-10-31
MX2025012789A (es) 2026-02-03
AU2024262149A1 (en) 2025-12-11
CN121368479A (zh) 2026-01-20

Similar Documents

Publication Publication Date Title
JP6760837B2 (ja) ジカルボン酸ビスアミド誘導体、その使用、それに基づく医薬組成物およびジカルボン酸ビスアミド誘導体の製造方法
WO2010036316A1 (en) Urea and carbamate compounds and analogs as kinase inhibitors
WO2002026743A1 (en) Novel pyridazine compounds for the treatment of diabetes
US20250276955A1 (en) Coronavirus main protease inhibitors and methods using same
KR102519948B1 (ko) 암 치료용 화합물 및 조성물
KR20240007144A (ko) 중수소화 dhodh 억제제
US20250312345A1 (en) Non-covalent inhibitors of the main protease of sars-cov-2 and methods of use
CN117769544A (zh) 多取代噻唑衍生物及其在疾病治疗中的应用
KR20110021799A (ko) Ｉｋｋ-베타 세린-트레오닌 단백질 키나아제의 억제제
IL324206A (en) Inhibitors of jun n-terminal kinases (jnk1, jnk2, and/or jnk3) and mitogen-activated protein kinases (mapk8, mapk9, and/or mapk10) and methods of using same
US20260049077A1 (en) Neurotrophic Receptor Tyrosine Kinase (NTRK) Inhibitors and Methods Using Same
US20240158355A1 (en) Bet subfamily inhibitors and methods using same
US20220193080A1 (en) Allosteric agonists and positive allosteric modulators of glucagon-like peptide 1 receptor
CN115003300A (zh) Jak抑制剂
US20260085063A1 (en) Benzamide compounds and methods of use thereof
US20200055871A1 (en) Activators of the retinoic acid inducible gene "rig-i" pathway and methods of use thereof
US20260125399A1 (en) Substituted Pyrazolo[3,4-b]pyridine Compounds and Methods of Use Thereof
US20250304550A1 (en) Bromodomain and extra-terminal (bet) subfamily bromodomain 1 (bd1) selective inhibitors and methods using same
TW202122400A (zh) Jak抑制劑
WO2025217249A1 (en) Methods for treating endometriosis and/or other ovary-related diseases and for monitoring treatment
EP4642451A2 (de) N-myristoyltransferasehemmer und verfahren zur verwendung
WO2025106722A1 (en) Inhibitors of stk33, ret, clk, and/or related kinases and methods using same
WO2025227071A1 (en) Methods and compositions for treating heart failure and liver disease
US20230399303A1 (en) Macrophage Migration Inhibitory Factor Inhibitors, and Methods of Making and Using Same
HK40125992A (zh) 神经营养受体酪氨酸激酶(ntrk)抑制剂及其使用方法